Hyperfibrinolysis and the risk of hemorrhage in stable cirrhotic patients

Asian Biomedicine

Volumn 4, Issue 2, 2010, Pages 199-206

  Surawong, Anoree ^a   Rojnuckarin, Ponlapat ^a   Juntiang, Jumlong ^a   Akkawat, Benjaporn ^a   Komolmit, Piyawat ^a   Intragumtornchai, Tanin ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Bleeding; Cirrhosis; Euglobulin lysis time; Hyperfibrinolysis; Survival

Indexed keywords

ALCOHOL; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FRUCTOSE BISPHOSPHATE;

ADULT; AGED; ARTICLE; ASCITES; BLEEDING; BLOOD CLOTTING TIME; COHORT ANALYSIS; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; IDIOPATHIC DISEASE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALIDITY; PROSPECTIVE STUDY; PROTHROMBIN TIME; THROMBOCYTE COUNT;

EID: 77957951586     PISSN: 19057415     EISSN: None     Source Type: Journal    
DOI: 10.2478/abm-2010-0027     Document Type: Article

References (23)

1. Comp PC, Jacocks RM, Rubenstein C, Radcliffe R. A lysine-absorbable plasminogen activator is elevated in conditions associated with increased fibrinolytic activity. J Lab Clin Med. 1981; 97: 637-45.
2. Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol. 1984; 37: 772-7.
3. Hersch SL, Kunelis T, Francis RB Jr. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood. 1987; 69: 1315-9.
4. Leebeek FW, Kluft C, Knot EA, de Maat MP, Wilson JH. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology. 1991; 101: 1382-90.
5. Gresele P, Binetti BM, Branca G, Clerici C, Asciutti S, Morelli A, et al. TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival. Thromb Res. 2008; 121: 763-8.
6. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost. 2001; 85: 667-70.
7. Reverter JC. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thromb Haemost. 2006; 4: 717-20.
8. Mannucci PM. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No J Thromb Haemost. 2006; 4: 721-3.
9. Violi F, Alessandri C, Ferro D, Saliola M, Cordova C, Musca A, et al. Interrelation between factor VII, prekallikrein, and hyperfibrinolysis in advanced cirrhosis. J Clin Pathol. 1989; 42: 1246-9.
10. Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology. 1992; 15: 672-6.
11. Violl F, Basili S, Ferro D, Quintarelli C, Alessandril C, Cordova C. Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. CALC Group. Thromb Haemost. 1996; 76: 177-83.
12. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol. 2001; 96: 1581-6.
13. Copley AL, Niewiarowski S, Marechal J. A micromethod of euglobulin fibrinolysis in plasma of human subjects and small laboratory animals. J Lab Clin Med. 1959; 53:468-73.
14. Toschi V, Rocchini GM, Motta A, Fiorini GF, Cimminiello C, Violi F, et al. The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites. Biomed Pharmacother. 1993; 47: 345-52.
15. Agarwal S, Joyner KA Jr, Swaim MW. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol. 2000; 95: 3218-24.
16. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol. 2007; 46: 727-33.
17. Ferguson JW, Helmy A, Ludlam C, Webb DJ, Hayes PC, Newby DC. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. Thromb Res. 2008; 121: 675-80.
18. Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. Hepatology. 1993; 17: 78-83.
19. Pernambuco JR, Langley P G, Hughes RD, Izumi S, Williams R. Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology. 1993; 18: 1350-6.
20. Booth NA. The natural inhibitors of fibrinolysis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, editors. Haemostasis and thrombosis. Singapore: Churchill Livingstone, 1994. p. 625-37
21. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006; 44: 217-31.
22. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006; 44: 440-5.
23. Aytac S, Turkay C, Bavbek N, Kosar A. Hemostasis and global fibrinolytic capacity in chronic liver disease. Blood Coagul Fibrinolysis. 2007; 18: 623-6.